India’s Dolutegravir prices rebounded during the first half of June after experiencing significant weakness in May. The recovery was driven by renewed procurement activity from downstream pharmaceutical manufacturers, improved restocking efforts, and greater stability in global logistics and geopolitical conditions. Buyers returned to the market following the earlier correction, helping absorb inventories and improve overall market sentiment. During May, the market faced pressure from increased domestic supply and subdued spot demand. Additional production capacity from major manufacturers expanded product availability, while formulation companies and export buyers delayed purchases ahead of upcoming tender and procurement cycles. Rising inventories across key pharmaceutical hubs further weakened seller leverage and contributed to softer market conditions. In June, demand improved as pharmaceutical companies resumed purchasing to meet ongoing formulation requirements. More balanced inventory levels and stable supply conditions also supported the market’s recovery. Looking ahead, analysts expect a gradual upward trend through the second half of June, supported by steady demand, continued procurement activity, and healthier market fundamentals.
